Does Fampridine improve fatigue in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Phase 2

• Conditions: chronic inflammatory demyelinating polyneuropathy (CIDP).; Neurological - Other neurological disorders; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12611000800921
• Lead Sponsor: niveristy of New South Wales

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Definitive diagnosis of CIDP
18-80 years of age.
Able to provide informed consent.

Exclusion Criteria

History of seizures.
Current treatment with anticonvulsant medication.
Pregnancy or lactation. Contraception is required in pre-menopausal female patients.
History of moderate-severe renal impairment.
Presence of serious psychiatric disorder (e.g major depression, bipolar disorder)
Enrolled in another clinical trial involving an investigational agent.
Known allergy to pyridine-containing substances.
History of renal dysfunction, with eGFR <60 ml.

Study & Design

• Study Type: Interventional
• Study Design: Not specified